Research Projects & Grants

  • IVIG Modulation of AntiHLA Antibody Response in Patients Awaiting Renal Transplantation, Role: PI, (07/1994 - 07/1995) Status: Completed
  • A Phase III/IV Multi-Center Controlled Open Label Randomized Study of the Safety and Efficacy of Somatropin (rhGH) to Improve Height Deficit Associated with Chronic Renal Insufficiency, Role: PI, (06/1993 - 06/1994) Status: Completed

College/University

  • The effects of growth hormone in children on maintenance dialysis, Role: PI, University of California, Los Angeles, (12/1998 - 12/1999) Status: Completed

Federal

  • Focal segmental glomerulosclerosis trial, Role: PI, National Institutes of Health/DHHS, (01/2008 - 01/2009) Status: Completed
  • TGF beta and the progression of renal disease, Role: PI, National Institutes of Health/DHHS, (05/2007 - 05/2008) Status: Completed
  • Evaluation of intravenous gamma globulin as an agent to lower allosensitization and improve allograft survival in highly-sensitized adult ESRD patients, Role: PI, National Institutes of Health/DHHS, (09/2002 - 09/2003) Status: Completed
  • Evaluation of Intravenous Gamma Globulin as an Agent to Lower Allosensitization and Improve Allograft Survival in Highly-Sensitized Pediatric ESRD Patients, Role: PI, National Institutes of Health/DHHS, (05/2002 - 05/2003) Status: Completed

For Profit Organization

  • An open-label, single-arm, multicenter study to ascertain the optimal starting dose of Mircera® given subcutaneously for the maintenance treatment of Anemia in pediatric patients with chronic kidney disease on dialysis or not yet on dialysis, Role: Investigator, Hoffmann-La Roche Inc., (04/2021 - 04/2022) Status: Completed
  • A retrospective observational study to describe changes in biochemical markers and occurrence of safety events following treatment with cinacalcet HCI in pediatric subjects with chronic kidney disease and secondary hyperparathyroidism receiving dialysis, Role: PI, Amgen, Inc., (11/2010 - 11/2011) Status: Completed
  • NCGS 85-036, substudy 11 Genentech National cooperative growth study (NCGS) post marketing surveillance program for nutropin depot® [somatropin (rDNA origin) for injection], nutropin AQ® [somatropin (rDNA origin) injection], nutropin® [somatropin (rDNA origin) for injection], and protropin® [somatrem for injection], Role: PI, Genentech, Inc., (04/2009 - 04/2010) Status: Completed
  • A Phase III, randomized, open-label, comparative, multi-center study to assess the safety and efficacy of Prograf (tacrolimus)/MMF, modified release (MR) tacrolimus/MMF and neoral (cyclosporine)/MMF in de novo kidney transplant recipients, Role: Investigator, Fujisawa, (02/2009 - 02/2010) Status: Completed
  • Luitpold Pharmaceuticals, Inc. – IVEN03017 – Comparison of the safety and efficacy of three Venofer® iron maintenance regimens in pediatric chronic kidney disease patients, Role: PI, Luitpold Pharmaceuticals, Inc., (11/2007 - 11/2008) Status: Completed
  • A three-month open-label, two-cohort study to investigate the safety and tolerability of myfortic in combination with neoral and tacrolimus in renal transplant recipients with GI intolerance, Role: Investigator, Novartis Pharmaceuticals Corporation, (11/2005 - 11/2006) Status: Completed
  • PEDS I (Pediatric eplerenone development study I): A randomized, double-blind, placebo withdrawal, parallel group, dose-response study to evaluate the efficacy and safety of eplerenone in the treatment of hypertension in children, Role: PI, Pfizer Inc., U.S. Pharmaceuticals Group, (08/2005 - 08/2006) Status: Completed
  • Use of Rituximab in pediatric solid organ recipients with post transplant lymphoproliferative disorders: an open label phase II multicenter non-randomized study, Role: Investigator, IDEC Pharmaceuticals Corporation, (01/2004 - 01/2005) Status: Completed
  • An open-label, randomized, non-inferiority study of novel erythropoiesis stimulating protein (NESP) and recombinant human erythropoietin (rHuEPO) for treatment of anemia in pediatric subjects with chronic renal insufficiency (CRI or end-stage renal disease (ESRD) receiving dialysis., Role: PI, Amgen, Inc., (12/2003 - 12/2004) Status: Completed
  • An open-label, multicenter study to further characterize the clinical utility and safety of rapamune and cyclosporine combination treatment in de novo renal allograft recipients (Project #0468E1, dated 01/12/99)., Role: Investigator, Wyeth-Ayerst Laboratories, (04/2000 - 04/2001) Status: Completed
  • A randomized, multicenter, comparative trial of prograf (Tacrolimus) in combination with rapamune (Sirolimus) or cellcept (Mycophenolate Mofetil) after kidney transplant, Role: Investigator, Fujisawa, Status: Completed
  • A randomized comparative trial of the effects of antilymphocyte induction on the tacrolimus plus mycophenolate mofetil maintenance immunosuppression after simultaneous kidney/pancreas transplantation, Role: Investigator, Fujisawa, Status: Completed

Internal

  • North American Pediatric Renal Trials Collaborative Studies (NAPRTCS), Role: Investigator, LLU Dept. of Pediatrics, (06/2024 - 06/2025) Status: Approved
  • Rituximab use in nephrotic syndrome, Role: Investigator, LLU Dept. of Pediatrics, (04/2016) Status: Completed
  • A prospective study of citrate based dialysate in pediatric patients receiving intermittent hemodialysis, Role: PI, LLU Dept. of Pediatrics, (04/2015 - 04/2016) Status: Completed
  • The role of PTH in renal osteodystrophy, Role: PI, LLU Dept. of Pediatrics, (10/2012 - 10/2013) Status: Completed
  • Mycophenolate mofetil in pediatric renal transplantation: non-induction vs. induction with basiliximab, Role: Investigator, LLU Dept. of Surgery, (01/2006 - 01/2007) Status: Completed
  • Use of Basiliximab with Mycophenolate Mofetil in kidney transplantation, Role: Investigator, LLU Transplantation Institute, (04/2003) Status: Completed
  • Antibody induction therapy in combination with mycophenolate mofetil in pediatric kidney transplantation, Role: Investigator, LLU Transplantation Institute, (04/2003) Status: Completed